244 related articles for article (PubMed ID: 22871982)
1. Preventing bone complications in prostate cancer.
Bishr M; Saad F
Curr Opin Support Palliat Care; 2012 Sep; 6(3):299-303. PubMed ID: 22871982
[TBL] [Abstract][Full Text] [Related]
2. Rationale for zoledronic acid therapy in men with hormone-sensitive prostate cancer with or without bone metastasis.
Saad F; McKiernan J; Eastham J
Urol Oncol; 2006; 24(1):4-12. PubMed ID: 16414486
[TBL] [Abstract][Full Text] [Related]
3. Maintaining bone health in prostate cancer throughout the disease continuum.
Saad F; Eastham J
Semin Oncol; 2010 Jun; 37 Suppl 1():S30-7. PubMed ID: 20682370
[TBL] [Abstract][Full Text] [Related]
4. Bone targeted therapies for the prevention of skeletal morbidity in men with prostate cancer.
Saylor PJ
Asian J Androl; 2014; 16(3):341-7. PubMed ID: 24435057
[TBL] [Abstract][Full Text] [Related]
5. Preservation of bone health in prostate cancer.
Lattouf JB; Saad F
Curr Opin Support Palliat Care; 2007 Oct; 1(3):192-7. PubMed ID: 18685362
[TBL] [Abstract][Full Text] [Related]
6. Skeletal-related events in metastatic prostate cancer and the number needed to treat: a critical consideration.
Schmitz-Dräger BJ; Weiss C; Ebert T; Dörsam J; Bismarck E
Urol Int; 2013; 90(3):329-33. PubMed ID: 23407093
[TBL] [Abstract][Full Text] [Related]
7. Health-economic review of zoledronic acid for the management of skeletal-related events in bone-metastatic prostate cancer.
Carter JA; Botteman MF
Expert Rev Pharmacoecon Outcomes Res; 2012 Aug; 12(4):425-37. PubMed ID: 22540167
[TBL] [Abstract][Full Text] [Related]
8. Skeletal complications of prostate cancer: pathophysiology and therapeutic potential of bisphosphonates.
Green JR
Acta Oncol; 2005; 44(3):282-92. PubMed ID: 16076701
[TBL] [Abstract][Full Text] [Related]
9. Management of bone metastases in patients with castration-resistant prostate cancer.
Cathomas R; Bajory Z; Bouzid M; El Ghoneimy A; Gillessen S; Goncalves F; Kacso G; Kramer G; Milecki P; Pacik D; Tantawy W; Lesniewski-Kmak K
Urol Int; 2014; 92(4):377-86. PubMed ID: 24802278
[TBL] [Abstract][Full Text] [Related]
10. Bisphosphonates for treatment and prevention of bone metastases.
Michaelson MD; Smith MR
J Clin Oncol; 2005 Nov; 23(32):8219-24. PubMed ID: 16278476
[TBL] [Abstract][Full Text] [Related]
11. Bone health and prostate cancer.
Saylor PJ; Smith MR
Prostate Cancer Prostatic Dis; 2010 Mar; 13(1):20-7. PubMed ID: 19901958
[TBL] [Abstract][Full Text] [Related]
12. Treatment and prevention of bone complications from prostate cancer.
Lee RJ; Saylor PJ; Smith MR
Bone; 2011 Jan; 48(1):88-95. PubMed ID: 20621630
[TBL] [Abstract][Full Text] [Related]
13. Understanding treatments for bone loss and bone metastases in patients with prostate cancer: a practical review and guide for the clinician.
Higano CS
Urol Clin North Am; 2004 May; 31(2):331-52. PubMed ID: 15123412
[TBL] [Abstract][Full Text] [Related]
14. Additive effect of zoledronic acid on serum prostate-specific antigen changes for hormone-sensitive prostate cancer patients with bone metastasis treated by combined androgen blockade.
Kamiya N; Suzuki H; Endo T; Takano M; Yano M; Naoi M; Nishimi D; Kawamura K; Imamoto T; Ichikawa T
Int J Urol; 2012 Feb; 19(2):169-73. PubMed ID: 22126137
[TBL] [Abstract][Full Text] [Related]
15. Adjuvant bone-targeted therapy to prevent metastasis: lessons from the AZURE study.
Coleman RE
Curr Opin Support Palliat Care; 2012 Sep; 6(3):322-9. PubMed ID: 22801464
[TBL] [Abstract][Full Text] [Related]
16. Bone Health and Bone-targeted Therapies for Prostate Cancer: a Programme in Evidence-based Care - Cancer Care Ontario Clinical Practice Guideline.
Alibhai SMH; Zukotynski K; Walker-Dilks C; Emmenegger U; Finelli A; Morgan SC; Hotte SJ; Winquist E;
Clin Oncol (R Coll Radiol); 2017 Jun; 29(6):348-355. PubMed ID: 28169118
[TBL] [Abstract][Full Text] [Related]
17. Skeletal-related events in prostate cancer.
Smith MR
Clin Adv Hematol Oncol; 2012 Aug; 10(8):535-6. PubMed ID: 23073052
[No Abstract] [Full Text] [Related]
18. Cost-effectiveness of denosumab vs zoledronic acid for prevention of skeletal-related events in patients with solid tumors and bone metastases in the United States.
Stopeck A; Rader M; Henry D; Danese M; Halperin M; Cong Z; Qian Y; Dansey R; Chung K
J Med Econ; 2012; 15(4):712-23. PubMed ID: 22409231
[TBL] [Abstract][Full Text] [Related]
19. New developments for treatment and prevention of bone metastases.
Body JJ
Curr Opin Oncol; 2011 Jul; 23(4):338-42. PubMed ID: 21519257
[TBL] [Abstract][Full Text] [Related]
20. Bone health in prostate cancer patients receiving androgen-deprivation therapy: the role of bisphosphonates.
Polascik TJ
Prostate Cancer Prostatic Dis; 2008; 11(1):13-9. PubMed ID: 17923854
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
